Toon Digneffe | Head Public Affairs & Public Policy
Takeda

Day 1 @ 09:10

Keynote panel: EU Pharmaceutical Legislation Revision – what’s new for 2026?

-       How will the revision affect rare diseases?

-       Navigating Europe’s regulatory incentives and the future of pharmaceutical R&D innovation

-       Who do we ensure that changes can facilitate Europe’s access, innovation and sustainability?

-       The European Biotech Act and its impact on rare diseases